Biotechnology Company
Appears in 1 story
Advancing WVE-007 from Phase 1 to Phase 2a
The biggest knock against today's blockbuster weight-loss drugs is that they burn muscle along with fat — up to 40% of the weight a patient loses on semaglutide can be lean tissue like muscle and bone. A new class of therapies now entering clinical trials attacks obesity through entirely different biology, targeting genes and metabolic pathways that strip fat while leaving muscle intact. On March 26, 2026, Wave Life Sciences reported that a single injection of its RNA-silencing drug WVE-007 cut visceral fat by 14.3% over six months while patients actually gained 2.4% lean mass — a profile no existing obesity drug can match.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
